Next Article in Journal
Functional Mobility Assessment in People with Multiple Sclerosis
Previous Article in Journal
Estrogen-Mediated Neural Mechanisms of Sex Differences in Burning Mouth Syndrome
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Neurology International
Volume 17
Issue 5
10.3390/neurolint17050062
neurolint-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice

by
Takafumi Tanei
1,2,*,
Shun Yamamoto
1,
Satoshi Maesawa
1,3,
Yusuke Nishimura
1,
Tomotaka Ishizaki
1,
Yoshitaka Nagashima
1,
Yoshiki Ito
1,
Miki Hashida
1,
Takahiro Suzuki
1,
Hajime Hamasaki
1,
Toshihiko Wakabayashi
2 and
Ryuta Saito
1
1
Department of Neurosurgery, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan
2
Department of Specialized Headache Outpatient, Nagoya Garden Clinic, Nagoya 451-0051, Japan
3
Department of Neurosurgery, National Hospital Organization, Nagoya Medical Center, Nagoya 460-0001, Japan
*
Author to whom correspondence should be addressed.
Neurol. Int. 2025, 17(5), 62; https://doi.org/10.3390/neurolint17050062
Submission received: 11 March 2025 / Revised: 19 April 2025 / Accepted: 21 April 2025 / Published: 22 April 2025
Browse Figures
Review Reports Versions Notes

Abstract

Background/Objectives: Lasmiditan is a newly developed drug for the acute treatment of migraine attacks, but factors associated with its efficacy remain unclear. This study aimed to confirm the efficacy of lasmiditan started at 50 mg under various dosing conditions and identify factors associated with its efficacy. Methods: There are four reasons for prescribing lasmiditan: as an add-on to triptan, if triptan is ineffective, if triptan produces side effects, and when triptan is contraindicated. Lasmiditan was administered at a dose of 50 mg. The efficacy of lasmiditan was defined as the disappearance of headache or a 50% or greater reduction in headache intensity within two hours after dosing. This study included 108 patients with migraines who took lasmiditan. Results: The results for efficacy and the side effects of lasmiditan were as follows: effective without side effects (22), effective with mild side effects (32), ineffective (14), and severe side effects (40). The efficacy rate of lasmiditan 50 mg was 50.0% (54/108). The following factors were found to be associated with lasmiditan’s efficacy: sex, migraine classification, calcium channel blockers, and anti-calcitonin gene-related peptide monoclonal antibody (CGRP-mAb) treatment. The overall incidence of side effects was 66.7%, and the dropout rate was 37.0%. Somnolence was more prevalent in the effective group, and other side effects were more prevalent in patients who dropped out due to the side effects of lasmiditan. Conclusions: Lasmiditan is likely to be effective in males with severe migraine classification and receiving CGRP-mAb treatment. If mild somnolence is a side effect, the drug can be continued and may be effective.
Keywords: lasmiditan; migraine; 50 mg lasmiditan; migraine; 50 mg

Share and Cite

MDPI and ACS Style

Tanei, T.; Yamamoto, S.; Maesawa, S.; Nishimura, Y.; Ishizaki, T.; Nagashima, Y.; Ito, Y.; Hashida, M.; Suzuki, T.; Hamasaki, H.; et al. Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice. Neurol. Int. 2025, 17, 62. https://doi.org/10.3390/neurolint17050062

AMA Style

Tanei T, Yamamoto S, Maesawa S, Nishimura Y, Ishizaki T, Nagashima Y, Ito Y, Hashida M, Suzuki T, Hamasaki H, et al. Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice. Neurology International. 2025; 17(5):62. https://doi.org/10.3390/neurolint17050062

Chicago/Turabian Style

Tanei, Takafumi, Shun Yamamoto, Satoshi Maesawa, Yusuke Nishimura, Tomotaka Ishizaki, Yoshitaka Nagashima, Yoshiki Ito, Miki Hashida, Takahiro Suzuki, Hajime Hamasaki, and et al. 2025. "Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice" Neurology International 17, no. 5: 62. https://doi.org/10.3390/neurolint17050062

APA Style

Tanei, T., Yamamoto, S., Maesawa, S., Nishimura, Y., Ishizaki, T., Nagashima, Y., Ito, Y., Hashida, M., Suzuki, T., Hamasaki, H., Wakabayashi, T., & Saito, R. (2025). Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice. Neurology International, 17(5), 62. https://doi.org/10.3390/neurolint17050062

Article Metrics

Back to TopTop